The development and availability of genomic applications for use in clinical care is accelerating rapidly. The routine use of genomic information, however, is beyond most health-care providers' formal training, and the challenges of understanding and interpreting genomic data are compounded by the demands of clinical practice. nearly all physicians, for example, agree that genetic variations may influence drug response, but only a small fraction feel adequately informed about pharmacogenomic testing.
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off-the-shelf technologies), proprietary external, and open standards. Off-the-shelf technologies are those provided, as designed, by a vendor. If a clinical system can integrate with external CDS (e.g., via an application programming interface), such technologies might provide additional functionality. External CDS technologies may include open-standards software and add-ons for purchase by clinical system vendors. For example, an external CDS technology may support the "infobutton" standard 8 that facilitates context-specific links to websites.
CDS technologies are designed with different CDS features and implemented using different configurations. Features of CDS interventions might include data entry for patient information through forms and templates, or reminders, alerts, and order sets, which can provide actionable content. Less often described, although still relevant CDS features, are those for data visualization or summarization. There are more granular descriptions for CDS features, for example, taxonomies describing backend capabilities 9 and the types of support that can be provided (i.e., front-end tools). 10 Such taxonomies should be referenced for a more detailed overview of possible CDS features available through clinical systems and can be leveraged to evaluate local systems. Individual CDS features may or may not be available, or they may be configured differently across institutions.
CDS configurations may be characterized as passive, semiactive, and active. These terms are synonymous with definitions for knowledge resources, information retrieval tools, and classic CDS described by the Agency for Healthcare Research and Quality. 11 We can describe configurations by the method in which patientspecific information is submitted and how patient-specific recommendations are generated. With passive CDS/knowledge resources, information submission and generation of recommendations are both manual processes. For semiactive CDS/ information retrieval, information submission is automated, and generation of recommendations is manual. Active CDS/ classic CDS involves automated information submission and automatically generated recommendation processes. CDS configurations and examples are summarized in Table 1 .
Frameworks, such as the ten key considerations for successful implementation proposed by Cresswell et al., 12 and the eight-dimension conceptual model proposed by Sittig and Singh, 13 might be useful for assessing implementation challenges and guiding local approaches to CDS implementation. In this perspective, we illustrate the application of Sittig and Singh's model to assess genomic CDS interventions.
The authors of this article represent participants within the eMERGE network who are uniquely suited to provide insight into common routes for delivering genomic CDS interventions, particularly to support genetic testing and data access processes within clinical information systems. We therefore focus on CDS solutions in the context of the workflow and communication dimension of the model. This dimension includes processes to assure patient care tasks are carried out efficiently. The following section provides an overview of genetic testing and data access processes. In 2008, the American Health Information Community's Personalized Health Care Workgroup and the Office of the national Coordinator for Health Information Technology published a "Personalized Healthcare Detailed Use Case, " describing the process of performing a genetic test with focuses on the exchange of personal health history, family health history, and genetic testing information between clinical providers and health-care consumers. 14, 15 Distinct from that work, we emphasize approaches to deliver genomic data using CDS embedded in the EHR/PHR during genetic testing and data access 
Phases of genetic testing and previous efforts to conceptualize the process of genetic testing
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processes. The following section provides insight into our rationale for establishing a common ground for discussing CDS solutions among heterogeneous IT infrastructures.
emeRGe Network
More than 20 relevant groups were recently brought together by the US national Institutes of Health national Human Genome Research Institute to share lessons from implementing genomic applications. 16 One important consensus reached by the group was that collaborative projects can help maximize the generalizability and usefulness of genomic medicine approaches. There are, however, heterogeneous IT infrastructures among collaborating institutions, which can pose challenges for replicating implementation strategies.
We believe a common ground for discussing genomic data delivery, which also encompasses variability among institutions, needs to be established in order to account for the heterogeneity of IT infrastructures. Motivated by the range of approaches used to report genomic data, members of the eMERGE network have, for example, summarized potential genomic data result-handling pathways. 17 The eMERGE network EHR integration workgroup plans to develop consensus and concepts for providing access to genomic applications, including EHR/PHR-linked decision support. Several sites in eMERGE and elsewhere have already developed genomic CDS, operating on structured genetic test results. [18] [19] [20] [21] [22] In the following section, we describe five examples from members of the eMERGE network and illustrate that common CDS configurations and technologies used to describe pregenomic CDS can also be used to characterize genomic CDS.
eXAmPLeS OF GeNOmiC CDS FROm tHe emeRGe NetWORK
Five illustrative examples and their CDS configurations are summarized in Table 1 . Examples from the institutions of the authors of this article include the warfarin dose schedule Web application (WarfarinDosing.org), infobutton-linked GeneInfo sheets, 23 the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) project, 19 the CLIPMERGE (Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics) program, 24 and the SMART (Substitutable Medical Apps Reusable Technologies) Genomics Advisor (http://smartplatforms.org/smart-app-gallery/genomics-advisor/). Three of these examples use external CDS technologies, two of which utilize open standards (the "infobutton" standard 8 and SMART architecture standards) for integrating into existing clinical systems. Websites such as WarfarinDosing.org provide a standalone external technology for passive CDS that allows users to input clinical and genomic variables to recommend a starting daily dose for warfarin. Such tools, however, require users to correctly transcribe and match variables and values within their EHR with those found on the website. GeneInfo sheets were created to provide actionable genetic information at the point of care. The sheets were created as a knowledge resource for a delimited set of use cases and are accessible through the Intermountain EHR system's infobutton architecture presented in the problem list and prescription order entry system. 23 This could be configured for OpenInfobutton, 8 which can be leveraged to deliver semiactive CDS across more EHR systems. The SMART Genomics Advisor is built using the SMART platform, which allows the insertion of nonvendor applications into otherwise-monolithic EHR products and which can be used to facilitate other forms of CDS. The SMART Genomics Advisor-augmented SMART Diabetes Monograph App, for example, provides a mashup of data and the calculation and visualization of single-nucleotide polymorphism data relevant for clinical care of diabetes. Genomics Advisor is available as a stand-alone external CDS technology or it can be integrated with other applications. Application developers have achieved integration with patient genetic data from an instance of openSnP (http://opensnp.org/). Currently, the SMART architecture enables "apps" to run against several EHRs, PHRs, and clinical data repositories that support the SMART application programming interface.
In addition to external CDS technologies, some institutions leverage CDS functionality provided within their local clinical systems. The PREDICT project, for example, utilizes the CDS functionality of its homegrown EHR, StarPanel, to provide active CDS. PREDICT was first launched in September 2010 and is currently designed to include both preemptive testing and "just in time, " indication-based testing. 19 To date, >11,000 individuals have been tested in PREDICT using the Illumina ADME platform, which includes 34 genes and 184 variants. Genomic CDS is currently available for five "drug-genome interactions": clopidogrel and CYP2C19 variants; simvastatin and SLCO1B1 variants; thiopurines and TPMT variants; tacrolimus and CYP3A5 variants; and warfarin and VKORC1, CYP2C9 variants. In contrast to the example provided above for passive warfarin CDS, by linking with the EHR, the PREDICT warfarin CDS can query the EHR for demographic variables, interacting medications, and genetic variants, and then calculate a recommended dose schedule.
Commercial clinical systems often also have off-the-shelf CDS functionality that can be leveraged. The CLIPMERGE project, for example, uses Epic Systems Best Practice Alert technology to deliver genome-informed dosing guidelines and guidelines for medication selection. Initially, the CLIPMERGE program focuses on delivering pharmacogenomic CDS and targets patients who are likely to have drug-genome interactions, including clopidogrel and CYP2C19 variants; warfarin and VKORC1, CYP2C9 variants; simvastatin and SLCO1B1 variants; tricyclic antidepressants and CYP2D6, CYP2C19 variants; and selective serotonin reuptake inhibitors and CYP2D6 variants. 24 Other universities are also developing similar systems with commercial EHRs. 7, 18, 25 Moreover, some clinical system vendors provide support for customized interface development that can be leveraged for other forms of CDS (e.g., Cerner MPages technology). This type of external CDS system is also the basis for the GeneInsight system 21 In addition to characterizing genomic CDS using common CDS frameworks for configurations and technologies, there are several lessons learned from implementing pregenomic CDS that can account for variation in health IT infrastructures and that are relevant for genomic CDS. We draw from the experiences of others to overcome challenges to CDS implementation.
LeSSONS FROm PReGeNOmiC CDS AND CHALLeNGeS FOR GeNOmiC CDS managing shared knowledge for CDS interventions
Early adopters of genomic medicine generally indicate a reliance on expert committees to survey the available evidence locally and further state that this process often leads to similar conclusions among different institutions. 16 Looking forward, we can learn from previous experiences with knowledge management for CDS interventions. Efforts such as the GuideLines Into DEcision Support 26 and the Clinical Decision Support Consortium 27 projects were established to circumvent duplicated efforts and should be leveraged to create sharable genomic CDS content. We can also benefit from the previous finding that collaborators did not accept knowledge management solutions provided by these projects without customization. 28 Given that the acceptance of knowledge management solutions will vary by institution, the Clinical Decision Support Consortium now provides editing tools and a legal framework to make the process more accessible. 29 The evolving nature of genomic knowledge also exacerbates the challenge of making knowledge management solutions accessible. For example, although commercial systems often provide off-the-shelf CDS functionality, 30 they currently require manual creation of CDS rules, which creates challenges to scaling up and maintaining the EHR CDS rule base. Scalable knowledge management solutions will require automated approaches to access, update, assess the quality, and document the provenance of knowledge.
improving the effectiveness of CDS interventions
Another challenge recognized by those with early experiences with genomic applications is a lack of institutional and clinician acceptance of the supporting evidence. 16 For this reason, in the PREDICT program, two of the early drug-genome interactions implemented (clopidogrel and warfarin) were validated within the EHR-linked DnA biorepository before implementation in the clinical workflow. 31, 32 The reason for doing this was twofold: (i) to counter potential local criticism of the "real-world applicability" of the genetic effect, and (ii) to locally train a multiethnic regression model for warfarin.
Apart from demonstrating the value of interventions, previous work with CDS suggests that user interface characteristics, information content, and integration with workflow and clinical decision-making processes may influence acceptance by health-care providers and should be explored in early validation efforts. [33] [34] [35] A report by the Agency for Healthcare Research and Quality examining fourteen factors associated with successful CDS systems 34 confirms and identifies new factors that favorably affect health-care processes. These include "cliniciansystem interaction features, " such as provision of decision support as part of clinician workflow, and "content features, " such as provision of a recommendation, rather than an assessment. 11 Although further understanding of how these features translate to acceptance of CDS is needed, we can still draw from these experiences when designing and conducting studies to validate genomic CDS. The avoidance of design issues such as information overload and "alert fatigue, " for example, will be particularly important to consider in the design of genomic CDS interventions. In addition, new CDS capabilities are needed.
With the possibility of a genetic test result and recommended action today being outdated tomorrow, CDS interventions can be leveraged to provide clinical users with educational materials that may support evidence-based practice, revised interpretations of genetic test results, and appropriate actions to take given these updates. Overby et al. 36 found that an existing taxonomy for assessing CDS system functional requirements may not cover a sufficient range of CDS capabilities when considering pharmacogenomics data. The taxonomy for example did not cover semiactive CDS capabilities. Although previous experiences with semiactive CDS indicate its underuse, semiactive CDS may provide a venue for clinical provider and health-care consumers to learn about new genomics evidence on an ongoing basis. Many suggestions for improving the effectiveness of CDS interventions proposed by Sittig et al. 38 should also be considered in the genomic CDS era. Suggestions for facilitating the use of complex patient data include the following: automatically summarizing patient data into a brief synopses of pertinent information; prioritizing and filtering recommendations to the user given both patient-and provider-specific data; and considering comorbidities to provide the most appropriate recommendations.
Decision support architecture and standard approaches for CDS interventions
Variation in decision support architecture also makes transferring successful interventions across institutions challenging. A review by Wright and Sittig indicates four architectures for CDS linked with clinical systems that track well chronologically. 39 The earliest architectures were stand-alone decision support systems, followed by decision support integrated into clinical systems, standards for sharing decision support content, and, most recently, service models. Even though the state of the art has evolved, all of these approaches continue to be built and used today. For all approaches, major difficulties exist in transferring successful interventions across institutions. We have learned from experiences with pregenomic CDS that standard terminologies, standard approaches to representing knowledge, and standard approaches to leverage knowledge are needed for effective scaling. 40 Use of standard terminologies such as the national Library of Medicine's Unified Medical Language System (http://www.nlm.nih.gov/research/umls) and the Logical Observation Identifiers names and Codes (http:// INVITED CommENTary loinc.org), for example, provide a language for communicating health-care concepts among systems. Standard approaches to represent knowledge, such as the Health Level 7 Arden Syntax standard for representing rules, 41 are needed to support translation into a computable format that can be used for CDS. Standard approaches to leveraging knowledge in a computable format to generate CDS, such as the Health Level 7 ContextAware Knowledge Retrieval ("Infobutton") standard, 8 also improve transportability and adaptability. One of the major challenges for genomic CDS is that the common approach used by laboratory medicine professionals-interpretation of genetic tests during the analytic phase, followed by generation of text reports-will not be sufficient to link genomic data with CDS technologies. Standards cannot be leveraged until genetic observations are captured in a computable, structured format.
Standard terminologies for the exchange of CDS interventions
There are limitations to using standard terminologies for pregenomic CDS that also apply to genomic CDS. Wright and Sittig highlighted the two main limitations in using standards: 39 (i) there are too many to choose from, and (ii) standards constrain what a user can encode to what was included in the scope of the standard. Similar to our previous experiences in the pregenomic era, there will also be many nonstandard approaches in implementing genomic CDS. We can learn from these experiences by leveraging CDS technologies that support existing terminologies to facilitate data exchange but that do not rely on emerging and incomplete standards. There is also a balance between structuring data and inclusion of contextual information. There exist standard terminologies such as those within the Logical Observation Identifiers names and Codes for structuring genetics data, including family history. Even so, it is relatively rare for family history information to be captured as structured text, due in part to difficulties in entering details as structured data and clinician perceptions of structured data as being difficult to interpret. 42 PHRs provide another venue for entering, reporting, retrieving, and displaying genealogy and genetic test data. Technologies such as GenePInG, 43 developed at Harvard-Massachusetts Institute of Technology, provide support for secure storage and sharing of these data.
It is clear that we can learn much from pregenomic CDS experiences and that we are able to leverage existing frameworks to characterize health IT infrastructures for CDS locally. Existing frameworks, however, do not appear to be sufficient to characterize implementation from the perspective of end-user workflow and communication processes considered in this commentary. In the following sections, we propose a framework for discussing opportunities for genomic CDS that support health-care provider-and consumer-initiated genetic testing and data access processes.
OPPORtUNitieS FOR GeNOmiC CDS
We can conceptualize genetic testing and data access processes within health IT infrastructures by considering two axes: (i) clinical system transaction initiation and (ii) stakeholder-driven clinical system interaction points. These axes are considered in Figure 1 , which illustrates opportunities for CDS interventions during genetic testing and data access processes.
Human-and computer-initiated clinical system transactions
Genetic testing during the preanalytic phase is most often human initiated (e.g., a clinical-care provider orders a genetic test). Test results from the analytic phase, including data interpretations, are then returned to the requestor during the postanalytic phase. The diseases and traits for which there are commercially available genetic tests have more than tripled in the past ten years, 44 and there are several institutions that currently or will soon have whole-genome or wholeexome sequencing data available from Clinical Laboratory Improvement Amendments-certified laboratories.
When either large-scale genotyping (e.g., from genome-wide association studies or focused drug metabolism genotyping/ sequencing platforms) or whole-genome/whole-exome sequencing are made available within EHRs, human-initiated steps during the preanalytic phase can be replaced by computer-initiated data retrieval. Subsequently, the analytic phase can be simplified to involve primarily data reanalysis and reinterpretation. During the postanalytic phase, filtered or "field-of-view" results can 
Stakeholder-driven clinical system interaction points and information needs
Clinical-care providers may interact with data through an EHR, whereas health-care consumers may do the same through a PHR. The goal of a PHR is to make health information accessible to patients; however, PHRs vary quite a bit in their design, functionality, and implementation. 45 For example, electronic PHRs may be "tethered" to facilitate data exchange with systems such as EHRs. Alternatively, PHRs may be untethered and installed on isolated personal computers. PHRs are relevant for this discussion given the fact that health-care consumers can initiate genetic testing through direct-to-consumer genetic testing services, and it is likely that use of direct-to-consumer testing will influence clinical-care provider decisions. 46, 47 Clinical-care providers and health-care consumers both need information to assess genetic testing options during the preanalytic phase of genetic testing. needs specific to clinical-care providers include knowledge for selecting a genetic test, for assessing risk, and for interpreting risk for a genetic condition using existing patient data. needs of health-care consumers might be educational in nature and may also include understanding what the results will tell them and whether they can be acted upon to improve health. In addition, health-care consumers may have practical information needs such as understanding how test results might affect their insurance and whether a direct-to-consumer laboratory is Clinical Laboratory Improvement Amendments certified.
During the postanalytic phase of genetic testing, clinical-care providers and health-care consumers need support for performing interpretations and care-planning activities. Specific needs for both include knowledge of the time when the results become available, interpretations of results in the context of a clinical action or health-care consumer goal, and knowledge of when updates to interpretations are made and applied to past data.
CONCLUSiON
Although there is heterogeneity among institutions integrating genomic CDS, there are common stakeholders, common genetic testing and data access processes, and common clinical system transactions for linking CDS. The eMERGE network EHR integration workgroup plans to develop consensus and concepts for providing access to genomic applications, including EHR/PHR-linked decision support. We provide examples of genomics CDS and illustrate that they can be characterized using common frameworks for CDS configurations and technologies. We also describe several lessons learned from implementing pregenomic CDS that can account for variation in health IT infrastructures and that are relevant for genomic CDS. Existing frameworks, however, do not appear to be sufficient to characterize implementation from the perspective of end-user workflow and communication processes. 
